Gephyrophobia is the anxiety disorder or specific phobia characterized by the fear of bridges and tunnels. As a result, sufferers of gephyrophobia  may avoid routes that will take them over bridges, or if they are a passenger, will act very apprehensively when passing over a bridge. The term gephyrophobia comes from the Greek γέφυρα (gephura), meaning "bridge", and  φόβος (phobos), meaning "fear".Some possible manifestations of gephyrophobia may be fear of driving off the bridge, fear of a gust of wind blowing one off the bridge, or fear that the bridge will collapse when crossing it (e.g., fear that the bridge lacks structural integrity). The fear overlaps with acrophobia (the fear of heights) as gephyrophobia tends to be exacerbated in taller bridges as compared to those closer to the water or ground beneath. Dr. Michael Liebowitz, founder of the Anxiety Disorders Clinic at the New York State Psychiatric Institute, says, "Its not an isolated phobia, but usually part of a larger constellation ... Its people who get panic attacks. You get light-headed, dizzy; your heart races. You become afraid that youll feel trapped." It is a situational phobia.As of 2008, the New York State Thruway Authority would lead gephyrophobiacs over the Tappan Zee Bridge. A driver could call the authority in advance and arrange for someone to drive their car over the bridge for them.
Based on these additional studies, the FDA granted in 2016 full approval and updated the label to include patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia for whom no other tyrosine kinase inhibitor therapy is indicated. Approval was also granted for T315I-positive and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia. Adverse effects
The United States Food and Drug Administration issued a partial clinical hold on new trial enrollment for ponatinib on October 9, 2013, due to an increased number of blood clots observed in patients taking the drug. The EPIC trial was later canceled on October 18. Subsequent studies of 449 patients treated during 4 years with ponatinib for chronic phase chronic myelogenous leukemia found the following adverse reactions. 150 Patients experienced cardiac vascular (21% of patients), peripheral vascular (12%), and cerebrovascular (9%) arterial occlusive events. Venous thromboembolic events occurred in 6% of patients. The most common all-grade adverse events included hypertension (69%), rash (63%), abdominal pain (48%), fatigue (47%), headache (43%), arterial ischemia (42%), dry skin (42%), constipation (41%), arthralgia (32%), nausea (28%), pyrexia (26%), peripheral neuropathy (24%), myalgia (24%), pain in extremity (23%), back pain (21%), and diarrhea (20%). In addition, there have been reported cases of the posterior reversible encephalopathy syndrome. Recently, an analogue of ponatinib was developed that retained anti-tumor efficacy but had reduced cardiovascular toxicity in experimental models.